Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

Recursion Pharmaceuticals' market cap currently stands at just over $2 billion. The math is simple: To double, the company will need its market cap to increase to more than $4 billion. The best way to ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human ...